Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (wegener's): A retrospective single-center study

Arthritis and Rheumatology

Volumn 66, Issue 10, 2014, Pages 2862-2870

  Azar, Lama ^a   Springer, Jason ^a   Langford, Carol A ^a   Hoffman, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLUENZA; INFUSION RELATED REACTION; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREMEDICATION; RASH; RECURRENCE FREE SURVIVAL; RELAPSE; REMISSION; RESPIRATORY DISTRESS; RETREATMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; THROAT TIGHTNESS; THROMBOCYTOPENIA; VIREMIA; VIRUS REACTIVATION; WEGENER GRANULOMATOSIS; AGED; ANALOGS AND DERIVATIVES; DRUG COMBINATION; GRANULOMATOSIS WITH POLYANGIITIS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AZATHIOPRINE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOLOGIC FACTORS; MALE; METHOTREXATE; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84908377306     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38744     Document Type: Article

References (30)

1. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
2. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
3. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-803.
4. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al, for the European Vasculitis Study Group. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
5. Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86: 269-77.
6. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
7. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
8. Specks U, Stone JH, for the RAVE-INT Research group. Long-term efficacy and safety results of the RAVE trial [abstract]. Clin Exp Immunol 2011; 164 Suppl 1: 65.
9. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3760-9.
10. Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-68.
11. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
12. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
13. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al, for the International Network for the Study of the Systemic Vasculitides (INSSYS). A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum 2001; 44: 912-20.
14. National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). August 2006. URL: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
15. Goek ON, Stone JH,. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 2005; 17: 257-64.
16. Sanders JS, Stassen PM, van Rossum AP, Kallenberg CG, Stegeman CA,. Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: tools for treatment decisions? Clin Exp Rheumatol 2004; 22: S94-101.
17. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31.
18. Walsh M, Flossmann O, Berden A, Westman K, Hoglund P, Stegeman C, et al, on behalf of the European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-8.
19. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
20. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-27.
21. Hiemstra TF, Walsh M, Mahr A, Savage CO, De Groot K, Harper L, et al, for the European Vasculitis Study Group (EUVAS). Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-8.
22. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F,. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
23. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM,. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis [published erratum appears in Arthritis Rheum 2013;65:1231]. Arthritis Rheum 2013; 65: 334-42.
24. Bernatsky S, Clarke AE, Suissa S,. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 2008; 168: 378-81.
25. Langford CA, Talar-Williams C, Sneller MC,. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-40.
26. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS,. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
27. Rhee EP, Laliberte KA, Niles JL,. Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5: 1394-400.
28. Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770-8.
29. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, Grasland A, Zoulim A, Le Guen J, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125-30.
30. Guillevin L, Pagnoux C, Karras A, Khoutra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis [abstract]. Arthritis Rheum 2012; 64 Suppl: S706.